

Table S4. Glycaemic variables before and after treatment with dopamine receptor antagonists in patients with prolactinomas.

Study (Ref.nr.)	Study	P-glucose baseline, mmol/L (SD)	P-glucose follow-up, mmol/L (SD)	HbA1c baseline, mmol/mol (SD)	HbA1c follow-up, mmol/mol (SD)	HOMA-IR baseline (SD)	HOMA-IR follow-up (SD)	Fasting p-insulin baseline, pmol/L (SD)	Fasting p- insulin follow-up, pmol/ L (SD)
Schwetz (25)	Schwetz	4.9 (0.2)	4.8 (0.1)	36.8 (2.2)	34.8 (5.2)	-	-	-	-
Auriemma II (26)	Auriemma II	5.3 (1.3)	5.2 (0.4)	-	-	4.1 (2.2)	1.8 (1.1)	119(47.2)	54.2 (29.2)
Medic (31)	Medic	-	-	-	-	-	-	-	-
Pala (27)	Pala	4.8 (0.5)	4.3 (0.3)	-	-	1.1 (1.3)	1.0 (0.5)	288 (379.2)	224(145.1)
Barbosa (33)	Barbosa	6.3 (2.6)	5.3 (2.1)	-	-	5.9 (5.0)	4.6 (3.8)	125 (92.0)	96.5 (64.2)
Auriemma (5)	Auriemma	5.0 (0.7)	4.7 (0.8)	-	-	3.2 (2.1)	1.2 (0.8)	96.5 (54.7)	38.3 (21.9)
Ciresi (4)	Ciresi	5.2 (0.8)	5.3 (1.0)	35.5 (16.9)	33.3 (19.1)	3.9 (1.5)	2.9 (1.0)	118 (46.9)	86.4 (25.9)
Inancli (29)	Inancli	-	-	-	-	1.8 (1.07)	1.6 (1.0)	-	-
Berinder (6)	Berinder	6.5 (1.9)	5.2 (0.6)	34.4 (11.5)	26.8 (8.2)	3.3 (2.3)	2.1 (0.7)	60.0 (27.0)	64.3 (23.3)
Silva (8)	Silva	6.3 (2.6)	5.2 (2.1)	-	-	5.8 (4.0)	4.6 (3.8)	125 (92)	98.6 (66.0)
Serri (7)	Serri	4.8 (0.3)	4.8 (0.4)	-	-	4.5 (1.9)	4.17 (1.6)	151 (61.1)	140 (52.5)
Yavuz (28)	Yavuz	4.4 (0.5)	4.2 (0.5)	-	-	2.1 (1.1)	1.5 (0.4)	75.7 (35.4)	56.6 (18.8)
Doknic (30)	Doknic	-	-	-	-	-	-	-	-
Iglesias (32)	Iglesias	5.2 (0.7)	5.2 (0.7)	-	-	-	-	-	-

(-) Not reported